Hemoglobinopathies Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin Variants), By Diagnosis, By Therapy, By Region, Competition, 2020-2030F

Description

The Global Hemoglobinopathies Market , valued at USD 8.44 Billion in 2024, is projected to experience a CAGR of 12.7% to reach USD 17.29 Billion by 2030. Hemoglobinopathies represent a group of inherited blood disorders characterized by abnormalities in the structure or production of the hemoglobin molecule, crucial for oxygen transport within red blood cells. The global market for these conditions is primarily driven by the increasing worldwide prevalence of these genetic disorders and significant advancements in diagnostic technologies and therapeutic interventions.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 8.44 Billion
Market Size 2030	USD 17.29 Billion
CAGR 2025-2030	12.7%
Fastest Growing Segment	Sickle Cell Disease
Largest Market	North America

Key Market Drivers

The global hemoglobinopathies market is significantly influenced by the increasing worldwide prevalence of these genetic disorders and the continuous emergence of novel and gene-based therapies. The rising prevalence contributes directly to a larger patient pool requiring diagnosis, treatment, and ongoing care, thereby expanding the overall market demand. According to The Lancet Haematology, in June 2023, the number of people living with sickle cell disease globally increased by 41.4% from 2000 to 7.74 million in 2021, highlighting a substantial and growing patient population. This demographic shift necessitates enhanced healthcare resources and drives investments in therapeutic solutions.

Key Market Challenges

The substantial cost associated with novel, advanced therapies, particularly gene therapies and bone marrow transplantation, represents a significant impediment to the global hemoglobinopathies market's expansion. These treatments, while offering the potential for transformative outcomes, are often accompanied by prohibitively high price tags. For instance, according to the Sickle Cell Disease Association of America, in December 2023, the list price for Casgevy, a gene therapy for sickle cell disease, was estimated at $2.2 million, while Lyfgenia, another gene therapy for the same condition, was estimated at $3.1 million.

Key Market Trends

Artificial intelligence is a significant trend, enhancing diagnostic precision and efficiency for hemoglobinopathies by streamlining complex data analysis. This technology leverages genetic information and medical records for quicker and more accurate disorder identification. While its potential is substantial, challenges remain; according to the National Institutes of Health, in August 2024, the best-performing AI models achieved only 21 percent accurate diagnoses from patient-written genetic condition descriptions, emphasizing areas for refinement. Despite these, AI proves impactful in personalized monitoring.

Key Market Players

Sangamo Therapeutics, Inc.
Pfizer, Inc. (Global Blood Therapeutics, Inc.)
bluebird bio, Inc.
Emmaus Medical, Inc.
Novartis AG
Prolong Pharmaceuticals, LLC
Sanofi S.A. (Bioverativ Inc.)
Gamida Cell Ltd.
Celgene Corporation
Abbott Laboratories, Inc.

Report Scope:

In this report, the Global Hemoglobinopathies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemoglobinopathies Market , By Type:

Thalassemia
Sickle Cell Disease
Other Hemoglobin (Hb) Variants

Hemoglobinopathies Market , By Diagnosis:

Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}
Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}
Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}

Hemoglobinopathies Market , By Therapy:

Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}
Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}
Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others}

Hemoglobinopathies Market , By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hemoglobinopathies Market .

Available Customizations:

Global Hemoglobinopathies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hemoglobinopathies Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants)
- 5.2.2. By Diagnosis (Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}, Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}, Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others})
- 5.2.3. By Therapy (Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}, Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}, Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others})
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Hemoglobinopathies Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Diagnosis
- 6.2.3. By Therapy
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Hemoglobinopathies Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Diagnosis
    - 6.3.1.2.3. By Therapy
- 6.3.2. Canada Hemoglobinopathies Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Diagnosis
    - 6.3.2.2.3. By Therapy
- 6.3.3. Mexico Hemoglobinopathies Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Diagnosis
    - 6.3.3.2.3. By Therapy

7. Europe Hemoglobinopathies Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Diagnosis
- 7.2.3. By Therapy
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Hemoglobinopathies Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Diagnosis
    - 7.3.1.2.3. By Therapy
- 7.3.2. France Hemoglobinopathies Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Diagnosis
    - 7.3.2.2.3. By Therapy
- 7.3.3. United Kingdom Hemoglobinopathies Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Diagnosis
    - 7.3.3.2.3. By Therapy
- 7.3.4. Italy Hemoglobinopathies Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Diagnosis
    - 7.3.4.2.3. By Therapy
- 7.3.5. Spain Hemoglobinopathies Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Diagnosis
    - 7.3.5.2.3. By Therapy

8. Asia Pacific Hemoglobinopathies Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Diagnosis
- 8.2.3. By Therapy
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Hemoglobinopathies Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Diagnosis
    - 8.3.1.2.3. By Therapy
- 8.3.2. India Hemoglobinopathies Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Diagnosis
    - 8.3.2.2.3. By Therapy
- 8.3.3. Japan Hemoglobinopathies Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Diagnosis
    - 8.3.3.2.3. By Therapy
- 8.3.4. South Korea Hemoglobinopathies Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Diagnosis
    - 8.3.4.2.3. By Therapy
- 8.3.5. Australia Hemoglobinopathies Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Diagnosis
    - 8.3.5.2.3. By Therapy

9. Middle East & Africa Hemoglobinopathies Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Diagnosis
- 9.2.3. By Therapy
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Hemoglobinopathies Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Diagnosis
    - 9.3.1.2.3. By Therapy
- 9.3.2. UAE Hemoglobinopathies Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Diagnosis
    - 9.3.2.2.3. By Therapy
- 9.3.3. South Africa Hemoglobinopathies Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Diagnosis
    - 9.3.3.2.3. By Therapy

10. South America Hemoglobinopathies Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Diagnosis
- 10.2.3. By Therapy
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Hemoglobinopathies Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Diagnosis
    - 10.3.1.2.3. By Therapy
- 10.3.2. Colombia Hemoglobinopathies Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Diagnosis
    - 10.3.2.2.3. By Therapy
- 10.3.3. Argentina Hemoglobinopathies Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Diagnosis
    - 10.3.3.2.3. By Therapy

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Hemoglobinopathies Market : SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Sangamo Therapeutics, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Pfizer, Inc. (Global Blood Therapeutics, Inc.)
15.3. bluebird bio, Inc.
15.4. Emmaus Medical, Inc.
15.5. Novartis AG
15.6. Prolong Pharmaceuticals, LLC
15.7. Sanofi S.A. (Bioverativ Inc.)
15.8. Gamida Cell Ltd.
15.9. Celgene Corporation
15.10. Abbott Laboratories, Inc.